Right bundle branch block; pericarditis; myocarditis; This is a literature report for the following literature source(s).   A 17 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BUNDLE BRANCH BLOCK RIGHT (medically significant), outcome "unknown", described as "Right bundle branch block"; PERICARDITIS (medically significant), outcome "unknown", described as "pericarditis"; MYOCARDITIS (medically significant), outcome "unknown", described as "myocarditis". The patient underwent the following laboratory tests and procedures: blood test: negative; c-reactive protein: 6.10 mg/dl; 5.0 mg/dl, notes: on admission; 4.06 mg/dl, notes: on discharge; cytomegalovirus test: negative; electrocardiogram: right bundle, notes: branch block; epstein-barr virus test: negative; influenza a virus test: negative; investigation: negative; parvovirus b19 test: negative; polymerase chain reaction: negative; respiratory syncytial virus test: negative; troponin i: 0.26 ng/dL; 1.05 ng/dL, notes: on admission; 0.45 ng/dL, notes: on discharge.  Additional information:The three cases at our hospital consisted of previously healthy male adolescents between the ages of 14 and 17 that presented with chest pain within 4 days of receiving their first or second mRNA covid-19 vaccine. On admission, they all had an abnormal electrocardiogram (ECG), elevated C-reactive protein (CRP), and elevated troponin I levels. Brain natriuretic peptide (BNP) levels were tested in two patients and found to be within normal limits. All patients had a normal echocardiogram, except for a residual patent foramen ovale in one patient. All patients showed down-trending troponin levels and inflammatory markers as well as complete resolution of symptoms before discharge on hospital day 4. All patients had normal troponin and CRP levels at post-discharge follow-up with an outpatient pediatric cardiologist visit. No causal relationship has been proven between the vaccine and myocarditis or pericarditis. Currently, the Centers for Disease Control and Prevention (CDC) continues to recommend the COVID-19 vaccination for anyone older than twelve years old as the known risks of illness and possible severe complications far outweigh having a possible rare adverse reaction.Suspected cases of myocarditis and pericarditis after COVID-19 vaccination should continue to be reported to VAERS.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.; Sender's Comments: Based on the available information, there is a reasonable possibility of a causal relationship between the suspect vaccine BNT162B2 (COMIRNATY) and reported events  which cannot be fully assessed/excluded. The case will be reassessed if additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202200283445 same article/drug and different patient/event;US-PFIZER INC-202200257419 same article/drug and different patient/event